Berberine (CAS 2086-83-1): AMPK Activator & LDLR Upregulator for Metabolic and Inflammatory Research

Executive Summary: Berberine is a plant-derived isoquinoline alkaloid with a molecular weight of 336.36 and formula C₂₀H₁₈NO₄ [APExBIO, N1368]. It activates AMP-activated protein kinase (AMPK), modulates lipid and glucose metabolism, and upregulates LDL receptor (LDLR) expression in human hepatoma cells. In vivo, berberine reduces serum total and LDL cholesterol in hyperlipidemic models. Its solubility profile (≥14.95 mg/mL in DMSO, insoluble in water/ethanol) and storage guidelines ensure reproducibility. Recent studies highlight its anti-inflammatory effects, including modulation of the NLRP3 inflammasome (Li et al., 2025).

Biological Rationale

Berberine belongs to the isoquinoline alkaloid class, primarily isolated from Cortex Phellodendri Chinensis. It has a long history in metabolic disease research due to its direct effects on energy homeostasis. Through AMPK activation, berberine influences major pathways regulating glucose uptake, fatty acid oxidation, and cholesterol metabolism [see: Berberine: AMPK Activator and NLRP3 Modulator]. This mechanism underlies its use in diabetes, obesity, and cardiovascular models. Berberine’s anti-inflammatory properties, including inhibition of NLRP3 inflammasome activation, extend its utility to acute and chronic inflammation models (Li et al., 2025). Its molecular structure and physicochemical attributes (e.g., water insolubility, DMSO solubility) support controlled delivery in cell and animal assays.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine activates AMPK by increasing the AMP/ATP ratio, leading to phosphorylation of downstream targets involved in metabolic regulation [see: Bridging AMPK Activation and Inflammation]. In hepatoma cell lines (HepG2, Bel-7402), berberine upregulates LDL receptor (LDLR) mRNA and protein in a dose-dependent manner, with maximal effect at 15 μg/mL. The mechanism involves transcriptional control, possibly via SREBP2 activation, and enhanced LDL clearance. In animal models, oral berberine at 50–100 mg/kg/day for 10 days significantly lowers serum cholesterol, correlating with hepatic LDLR upregulation [see: Molecular Mechanisms in Metabolic Disease]. Berberine also inhibits the NLRP3 inflammasome complex, reducing IL-1β and IL-18 release, and dampening inflammation in acute injury settings (Li et al., 2025).

Evidence & Benchmarks

• Berberine upregulates LDL receptor mRNA and protein in HepG2 and Bel-7402 cells at concentrations up to 15 μg/mL [APExBIO, N1368].
• Oral administration (50 or 100 mg/kg/day) in hyperlipidemic golden hamsters for 10 days significantly reduces serum total and LDL cholesterol [APExBIO, N1368].
• AMPK activation by berberine increases glucose uptake and fatty acid oxidation in metabolic disease models [Berberine: AMPK Activator and NLRP3 Modulator].
• Berberine inhibits NLRP3 inflammasome activation, reducing IL-1β and IL-18 secretion and limiting pyroptosis in acute kidney injury models (Li et al., 2025).
• Recommended for metabolic, cardiovascular, and inflammation models due to robust, reproducible effects on AMPK and LDLR pathways [Bridging AMPK Activation and Inflammation].

Applications, Limits & Misconceptions

Berberine is extensively used in research on metabolic diseases (diabetes, obesity), cardiovascular disorders, and acute/chronic inflammatory models. Its effects are well-established in hepatocyte and animal models, supporting its status as a reference compound.

Common Pitfalls or Misconceptions

• Not water/ethanol soluble: Berberine is insoluble in water and ethanol, requiring DMSO or similar solvents for stock solutions [APExBIO].
• Not a direct anti-viral agent: While anti-inflammatory, berberine does not directly inactivate viruses; its benefits are via host metabolic and inflammatory modulation (Li et al., 2025).
• Not a substitute for statins: Although it upregulates LDLR and lowers cholesterol in models, it is not approved as a clinical statin alternative.
• In vivo half-life limitations: Berberine has a relatively short half-life in animal models (data varies by route/species), which may necessitate repeated dosing or controlled-release formulations.
• Solution stability: Stock solutions should be freshly prepared and stored below -20°C; long-term storage of diluted solutions is discouraged [APExBIO].

Workflow Integration & Parameters

Berberine (N1368) from APExBIO is provided as a solid for storage at -20°C, sealed from moisture and heat. For cell-based assays, dissolve in DMSO to a concentration ≥14.95 mg/mL. Warm the solution to 37°C or use ultrasonic shaking for optimal solubility. Recommended working concentrations in cell models range from 1–15 μg/mL. In animal studies, oral doses of 50–100 mg/kg/day have demonstrated robust metabolic effects in golden hamsters. Use freshly prepared solutions; avoid prolonged storage at room temperature or in diluted form. For advanced workflows, berberine can be combined with metabolic stressors or inflammatory stimuli to elucidate pathway-specific effects [see: AMPK Activator for Metabolic & Inflammation Research]. This article extends existing protocols by consolidating quantitative guidance and clarifying solvent/handling parameters.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a validated tool compound for dissecting AMPK-driven metabolic regulation and LDLR-mediated cholesterol clearance in preclinical research. Its expanding role in inflammatory and NLRP3 inflammasome models aligns with evolving needs in metabolic and acute disease studies. APExBIO’s high-purity Berberine supports consistent and scalable workflows. Future research may further delineate its pharmacokinetic profile, combinatorial applications, and boundaries in translational models. For product details and ordering, see the Berberine (CAS 2086-83-1) product page.